-
Feb 11, 2026
-
Feb 8, 2026
-
New module streamlines standardized CRF (case report form) design and EDC build to help clinical teams start studies faster.
Feb 5, 2026
-
Valley Diagnostics Ltd., a Welsh diagnostics company commercialising next-generation point-of-care lateral flow tests (LFTs), has signed several licencing agreements with its research partner and collaborator Aberystwyth University to bring to market innovative diagnostic tests that will revolutionise disease detection.
Feb 5, 2026
-
Feb 4, 2026
-
Feb 4, 2026
-
The addition of BrightHeart's B-Right AI Platform to the Voluson Solution store is poised to improve early detection of congenital defects, reduce diagnostic uncertainty, and ultimately support better outcomes for clinicians, expectant parents and their babies.
Feb 4, 2026
-
Feb 2, 2026
-
BetterWay blood testing by Babson Diagnostics will launch a GLP-1 test panel at more than 25 retail locations in Austin and Temple, including Sam’s Club and Peoples Rx pharmacies.
Feb 2, 2026
-
• Acquisition strengthens Astoriom’s stability storage capabilities to meet increasing demand across North America
• Offers reliable, compliant, and accessible solutions to advance scientific discovery and product development
Jan 26, 2026
-
Dr. Hafez will lead the new early-phase research site at Los Angeles Cancer Network, one of the nation’s largest and most diverse community-based oncology practices.
Jan 25, 2026
-
4D Path, a company dedicated to personalizing cancer care through a novel, physics-inspired approach to predicting tumor response to therapy, today announced its participation as an exploratory biomarker collaborator in the Phase II DAD-IO clinical study (NCT04724018) led by Dana-Farber Cancer Institute and supported by Gilead Sciences, Inc. This high-profile study is evaluating a novel combination therapy for patients with locally advanced or metastatic urothelial carcinoma (mUC), including bladder cancer, and represents an important step forward in 4D Path’s mission to redefine precision oncology.
Jan 21, 2026
-
Jan 22, 2026
-
Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing, announced its support for the Genomic Answers for Children’s Health Act. This legislation, introduced in the House of Representatives with bipartisan support, aims to improve access to genomic sequencing by clarifying that such testing is covered under Medicaid’s “Early and Periodic Screening, Diagnostic, and Treatment Services” for children meeting certain clinical criteria.
Jan 15, 2026
-
• Inaugural event takes place from 9–10 March at Hinxton Hall in Cambridge, UK
• Programme spans neurological disorders, sensory diseases, rare conditions, and cancer immunotherapy
Jan 19, 2026
-
CluePoints, provider of leading statistical and AI-driven software solutions, has appointed Sinead Godkin as its new Chief People Officer (CPO).
Jan 19, 2026
-
Gifthealth has announced the appointment of Jeremy Richardson as its new Chief Commercial Officer (CCO).
Jan 12, 2026
-
Strategic appointment to support global scale-up of sample management operations
Jan 12, 2026
-
Jan 12, 2026
-
Cycle and Inceptua have announced the expansion of their partnership to make NITYR® tablets available via a Free Goods Programme for eligible patients with HT-1 and AKU to include Morocco and Egypt.
Jan 11, 2026